CAR T-Cell Immunotherapy Named Advance of the Year in Annual ASCO Report

A new and unique new way to treat cancer – CAR T-cell therapy – is poised to transform the outlook for children and adults with certain otherwise incurable cancers. The American Society of Clinical Oncology (ASCO) named this type of adoptive cell immunotherapy the Advance of the Year in its annual report. Released within the scope of the World Cancer Day, Clinical Cancer Advances 2018 highlights the most impactful clinical cancer research and policy developments over the past year.

CAR T-cell therapy is a treatment that uses a patient’s own white blood cells, which have been genetically reprogrammed in the lab to fight their own cancer. In 2017, the U.S. Food and Drug Administration (FDA) approved two CAR T-cell therapies, to treat children and young adults with acute lymphoblastic leukemia and adults with diffuse large B-cell lymphoma.

The full press release is available here.